Houston、TXにおける膀胱癌の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、膀胱癌に関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- University of Texas MD Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- UT MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
被験者募集中第2相
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
被験者募集中第1/2相
- Texas Oncology - Gulf Coast, Houston
- Texas Oncology - Gulf Coast, Houston
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
被験者募集中第1相
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
被験者募集中第2相
- Houston Methodist, Houston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
被験者募集中第2相
- Houston Metro Urology, Houston
- Houston Methodist Hospital, Houston
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
被験者募集中第3相
- Houston Metro Urology, Houston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Measuring Surgical Recovery After Radical Cystectomy
被験者募集中観察研究
- University of Texas MD Anderson Cancer Center, Houston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
被験者募集中第3相
- M D Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- The University of Texas, MD Anderson Cancer Center, Houston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
被験者募集中第1/2相
- Houston Metro Urology, Houston
- Houston Methodist Hospital - Department of Urology, Houston
- University of Texas - MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- University of Texas MD Anderson Cancer Center, Houston
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center, Houston
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
被験者募集中第1相
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
被験者募集中第2相
- Houston Methodist Neal Cancer Center, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
被験者募集中観察研究
- Md Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
被験者募集中第1相
- Baylor St. Luke's Medical Center, Houston
Blue Light Cystoscopy With Cysview® Registry
被験者募集中観察研究
- Michael E. DeBakey VA Medical Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Houston
他の都市における膀胱癌の試験
- New York City, NY35件の研究
- Nashville, TN31件の研究
- Dallas, TX27件の研究
- Boston, MA26件の研究
- Washington, DC26件の研究
- Los Angeles, CA24件の研究
- Baltimore, MD24件の研究
- St. Louis, MO22件の研究
- Philadelphia, PA21件の研究
- Seattle, WA21件の研究
- Edison, NJ21件の研究
- Chicago, IL21件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。